Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter, pilot study of pembrolizumab, exemestane, and
leuprolide for subjects being resistant for front-line hormonal therapy for inoperable
locally advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth
factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the
final tolerability and preliminary efficacy analysis. The efficacy objectives including PFS,
overall response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR).
Adverse effects will be recorded according to CTCAE v4.0.